Neuroendocrine

Houston, TX and Plano, TX, Jan. 03, 2022 (GLOBE NEWSWIRE) -- RadioMedix and Orano Med are pleased to announce the initiation of the Phase II clinical trial of AlphaMedix™ with the treatment of the first patient on December 21st, 2021. …

Progression-free survival (PFS) in extrapancreatic neuroendocrine tumors (NETs) improved significantly with the addition of an angiogenesis inhibitor to standard endocrine therapy,…

HONG KONG and FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has initiated SURTORI-01, a Phase III study to evaluate the efficacy and…

The use of the tyrosine kinase inhibitor (TKI) sunitinib (Sutent) significantly improved progression-free survival (PFS) in patients with malignant pheochromocytoma and paraganglioma…

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 19, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has initiated a Japan registration-enabling bridging study…

The retrospective study analyzed the health data of 8,607 patients (stored at ICES). This population-based cohort study is the ‘New study reveals different mortality patterns of neuroendocrine tumors (NETs). This would help inform…

Dramatic improvement in progression-free survival (PFS) for progressive midgut neuroendocrine tumors (NETs) failed to translate into significantly better overall survival (OS),…

– U.S. FDA has assigned a target action date of April 30, 2022 – – If approved, surufatinib would be HUTCHMED’s first novel oncology drug marketed outside of China – HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 01,…

– Second New Drug Application (“NDA”) approved for Sulanda in China – – The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51% in patients with advanced pancreatic NET – HONG…